Minimal Residual Disease (MRD) follow up of MM patients obtaining stringent complete remission (sCR) in the NMSG/EMN02 clinical trial – defining sCR numbers and prediction of disease progression by multiparametric flow cytometry (MFC).

Hans Erik Johnsen(Herlev Hospital), Karen Dybkær(Aalborg University Hospital), Rasmus Froberg Brøndum(Aarhus University), E. Myhr, Carsten Helleberg(Herlev Hospital), Niels Smedegaard Andersen(Rigshospitalet), Bronno van der Holt(Erasmus MC), Lucia Ahlberg(Nordic Myeloma Study Group), Y. Hammerlund, C. Fransson, Rosaria Renna(University of Sannio), Vincent H. J. van der Velden(Erasmus MC), Helle Høholt, Andreas Jönsson, Damian Szatkowski, Susanne K. Kjær(Copenhagen University Hospital), I. Lonn, Anja Klostergaard, Henning Sand Christensen, Maria Hansson(Lund University), T Sjögren, Anders Waage(St Olav's University Hospital), Davine Hofste op Bruinink(Erasmus MC), Björn Andréasson(NU Hospital Group), S. Faxoe, V. Karlsson, Hans Gregersen(California Medical Innovations Institute), Niels Abildgaard(University of Southern Denmark), Alexander Schmitz(Chr. Hansen (Denmark)), Mette Holst(Aalborg University Hospital), Einar Haukaas, Louise Hvilshøj Madsen, Lena Brandefors, S. Vangsted, Julie Støve Bødker(Chr. Hansen (Denmark)), U-H Mellqvist(University of Gothenburg), Martin Bøgsted(Chr. Hansen (Denmark)), Asta Svirskaite, Fredrik Schjesvold(Oslo University Hospital), M. Friestad, Hans Christiansen(Medizinische Hochschule Hannover), Stig Lenhoff(Lund University), Mark Hector(University of Dundee), Pieter Sonneveld(Erasmus MC Cancer Institute), B. Højlund Pedersen, Birgitta Lauri(Sunderby sjukhus)

VBN Forskningsportal (Aalborg Universitet)

January 1, 2018

Cited by 0

|Journal of Clinical Oncology|2005|2.9k

|Leukemia|2006|2.6k

|Journal of Clinical Oncology|2015|2.2k

|The Lancet|2019|1.3k

|The American Journal of Human Genetics|2018|1.2k

Related Papers